Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Conjugated Proteins02:50

Conjugated Proteins

Simple proteins and protein complexes contain only amino acids. In contrast, many other proteins, called conjugated proteins, covalently bond with non-protein moieties.
Nucleoproteins are protein complexes that contain nucleic acids, categorized as deoxyribonucleoproteins (DNPs) or ribonucleoproteins (RNPs) respectively. The nucleosome is a typical example of a DNP where nuclear DNA is associated with histone proteins. The major antigen for the Covid-19 virus SARS-CoV is an RNP that is critical...
Vaccine Production01:23

Vaccine Production

Vaccine production involves a sequence of upstream and downstream processes to generate a safe and effective immunological product. It begins with cultivating microorganisms, such as viruses or bacteria, to obtain antigenic material. For viral vaccines, mammalian host cells are grown in bioreactors and subsequently infected with the target virus. The virus replicates within the host cells, which are lysed to release viral particles. This lysate is then clarified through filtration or...
Coronavirus01:29

Coronavirus

Coronaviruses, including the severe acute respiratory syndrome coronavirus (SARS-CoV), are enveloped viruses characterized by their single-stranded, positive-sense RNA genome and helical nucleocapsid structure. The hallmark of these viruses is their club-shaped spike (S) glycoproteins that protrude from the viral envelope, facilitating attachment to host cells. Typically, coronaviruses infect the upper respiratory tract, often causing mild or asymptomatic disease. However, certain strains like...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The utility of artificial intelligence for DNA variant curation in the Mendelian genetic disorder familial hypercholesterolaemia.

Pathology·2026
Same author

Toddlers' Active Gaze Behavior Supports Self-Supervised Object Learning.

Developmental science·2026
Same author

Vaccine uptake in the context of mandate announcement and removal: Evidence from Europe and North America.

Vaccine·2026
Same author

Optimizing Bispecific Antibody Expression via Multi-Omics Analysis and Vector Redesign.

Biotechnology and bioengineering·2026
Same author

ClimActor 2.0: A spatialized database of subnational climate pledges and emissions data.

Scientific data·2026
Same author

SEC-seq reveals translation-focused metabolic strategies for high IgG productivity in clonal CHO cells.

bioRxiv : the preprint server for biology·2026

Related Experiment Video

Updated: Jul 26, 2026

Production of E. coli-expressed Self-Assembling Protein Nanoparticles for Vaccines Requiring Trimeric Epitope Presentation
10:58

Production of E. coli-expressed Self-Assembling Protein Nanoparticles for Vaccines Requiring Trimeric Epitope Presentation

Published on: August 21, 2019

7.6K

Process development of a SARS-CoV-2 nanoparticle vaccine.

Diandra Martinez-Cano1, Rashmi Ravichandran2,3, Huong Le1

  • 1Process Development, Amgen Inc., Amgen Center Drive, Thousand Oaks, CA 91320, USA.

Process Biochemistry (Barking, London, England)
|April 4, 2023
PubMed
Summary

Rapid development of a SARS-CoV-2 vaccine using a novel protein nanoparticle platform accelerated timelines. This academia-industry collaboration offers a model for future pandemic preparedness and efficient biologic manufacturing.

Keywords:
COVID-19First-in-humanNanoparticle vaccineProcess developmentSARS-CoV-2

More Related Videos

A "Plug-And-Display" Nanoparticle Vaccine Platform Based on Outer Membrane Vesicles Displaying SARS-CoV-2 Receptor-Binding Domain
08:07

A "Plug-And-Display" Nanoparticle Vaccine Platform Based on Outer Membrane Vesicles Displaying SARS-CoV-2 Receptor-Binding Domain

Published on: July 25, 2022

2.6K
Production of a SARS-CoV-2 Virus-Like-Particle System to Investigate Viral Life Cycles In Vitro
09:26

Production of a SARS-CoV-2 Virus-Like-Particle System to Investigate Viral Life Cycles In Vitro

Published on: June 6, 2025

464

Related Experiment Videos

Last Updated: Jul 26, 2026

Production of E. coli-expressed Self-Assembling Protein Nanoparticles for Vaccines Requiring Trimeric Epitope Presentation
10:58

Production of E. coli-expressed Self-Assembling Protein Nanoparticles for Vaccines Requiring Trimeric Epitope Presentation

Published on: August 21, 2019

7.6K
A "Plug-And-Display" Nanoparticle Vaccine Platform Based on Outer Membrane Vesicles Displaying SARS-CoV-2 Receptor-Binding Domain
08:07

A "Plug-And-Display" Nanoparticle Vaccine Platform Based on Outer Membrane Vesicles Displaying SARS-CoV-2 Receptor-Binding Domain

Published on: July 25, 2022

2.6K
Production of a SARS-CoV-2 Virus-Like-Particle System to Investigate Viral Life Cycles In Vitro
09:26

Production of a SARS-CoV-2 Virus-Like-Particle System to Investigate Viral Life Cycles In Vitro

Published on: June 6, 2025

464

Area of Science:

  • Biotechnology
  • Vaccinology
  • Protein Engineering

Background:

  • The COVID-19 pandemic necessitated accelerated development of therapeutics and vaccines.
  • Traditional biomanufacturing timelines, especially for non-antibody biologics, are lengthy.
  • Existing platforms for monoclonal antibody development offer a model for accelerated timelines.

Purpose of the Study:

  • To describe the rapid development of a robust process for a two-component self-assembling protein nanoparticle vaccine for SARS-CoV-2.
  • To demonstrate an effective academia-industry partnership model for rapid pandemic response.
  • To highlight a strategy for improving future pandemic preparedness.

Main Methods:

  • Leveraged existing, robust platforms for upstream and downstream processes, analytical methods, and formulation.
  • Employed a transient cell line for early material supply.
  • Utilized a stable cell pool for toxicology study material manufacturing.

Main Results:

  • Successfully developed a robust and reproducible manufacturing process for a SARS-CoV-2 protein nanoparticle vaccine.
  • Achieved accelerated development timelines, significantly shorter than traditional methods.
  • Demonstrated the efficacy of an academia-industry partnership in rapid response to a global health crisis.

Conclusions:

  • The described process enables rapid development of protein nanoparticle vaccines.
  • The academia-industry collaboration model is effective for swift pandemic response.
  • This approach can enhance future preparedness for emerging infectious disease threats.